Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice

Kidney International

Volumn 86, Issue 5, 2014, Pages 979-990

  Barutta, Federica ^a   Grimaldi, Serena ^a   Franco, Irene ^b   Bellini, Stefania ^a   Gambino, Roberto ^a   Pinach, Silvia ^a   Corbelli, Alessandro ^c   Bruno, Graziella ^a   Rastaldi, Maria Pia ^c   Aveta, Teresa ^d   Hirsch, Emilio ^b   Di Marzo, Vincenzo ^d   Gruden, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d CNR   (Italy)

Author keywords

albuminuria; chemokine receptor; chronic kidney disease; diabetic nephropathy; fibrosis; inflammation

Indexed keywords

CANNABINOID 2 RECEPTOR; CREATININE; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYLGLUCOSAMINE; NEPHRIN; PODOCIN; CCL2 PROTEIN, MOUSE; CCR2 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR2; CNR2 PROTEIN, MOUSE; STREPTOZOCIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOWN REGULATION; EXCRETION; EXTRACELLULAR MATRIX; IN VITRO STUDY; KIDNEY DYSFUNCTION; KNOCKOUT MOUSE; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; COMPLICATION; DEFICIENCY; DIABETIC NEPHROPATHIES; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENETICS; GLOMERULUS; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; TIME; URINE;

ACETYLGLUCOSAMINE; ALBUMINURIA; ANIMALS; BONE MARROW TRANSPLANTATION; CELL LINE; CELL PROLIFERATION; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FEMALE; KIDNEY GLOMERULUS; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; PODOCYTES; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CCR2; STREPTOZOCIN; TIME FACTORS;

EID: 84908593675     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.165     Document Type: Article

References (42)

1. Molitch ME, DeFronzo RA, Franz MJ, et al. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27: S79-S83
2. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972
3. Giunti S, Barutta F, Perin PC, et al. Targeting the MCP-1/CCR2 system in diabetic kidney disease. Curr Vasc Pharmacol 2010; 8: 849-860
4. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307
5. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030
6. Tarabra E, Giunti S, Barutta F, et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-Treated mice and human cultured podocytes. Diabetes 2009; 58: 2109-2118
7. Miceli I, Burt D, Tarabra E, et al. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 2010; 298: F381-F390
8. Barutta F, Corbelli A, Mastrocola R, et al. Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes 2010; 59: 1046-1054
9. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1-24
10. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434: 782-786
11. Muñoz-Luque J, Ros J, Fernández-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-483
12. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009; 60: 1129-1136
13. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755
14. Calkin A, Giunti S, Jandeleit-Dahm K, et al. PPAR-A and-g agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006; 21: 2399-2405
15. Barutta F, Piscitelli F, Pinach S, et al. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 2011; 60: 2386-2396
16. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiol 2006; 211: 609-618
17. Agudo J, Martin M, Roca C, et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010; 53: 2629-2640
18. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011; 121: 2181-2196
19. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 2006; 17: 2383-2389
20. Kalluri R, Shield CF, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997; 99: 2470-2478
21. Teixeira-Clerc F, Belot MP, Manin S, et al. Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 2010; 52: 1046-1059
22. Defer N, Wan J, Souktani R, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 2009; 23: 2120-2130
23. Mukhopadhyay P, Rajesh M, Pan H, et al. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 2010; 48: 457-467
24. Burt D, Salvidio G, Tarabra E, et al. The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am J Pathol 2007; 171: 1789-1799
25. Racz I, Nadal X, Alferink J, et al. Crucial role of CB2 cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci 2008; 28: 12125-12135
26. Tam J, Liu J, Mukhopadhyay B, et al. Endocannabinoids in liver disease. Hepatology 2011; 53: 346-355
27. Pacher P, Mukhopadhyay P, Mohanraj R, et al. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52: 601-607
28. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease-successes and failures. FEBS J 2013; 280: 1918-1943
29. Horváth B, Mukhopadhyay P, HaskóG, et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 2012; 180: 432-442
30. Gonsiorek W, Lunn C, Fan X, et al. Endocannabinoid 2-Arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 2000; 57: 1045-1050
31. Zhou Y, Kong X, Zhao P, et al. Peroxisome proliferator-Activated receptora is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 2011; 79: 1302-1311
32. Zuo Y, Yang HC, Potthoff SA, et al. Protective effects of PPARg agonist in acute nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 174-181
33. Park CW, Kim HW, Ko SH, et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-Activated receptor-A. Diabetes 2006; 55: 885-893
34. Ren S, Xin C, Beck KF, et al. PPARa activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 2005; 338: 1818-1824
35. Nam DH, Lee MH, Kim JE, et al. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 2012; 153: 1387-1396
36. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 2006; 48: 519-526
37. Horvátha B, Mukhopadhyaya P, Kechrida M, et al. Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptordependent manner. Free Radic Biol Med 2012; 52: 1325-1333
38. Shankland SJ, Pippin JW, Reiser J, et al. Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36
39. Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci USA 1997; 94: 12112-12116
40. Barutta F, Pinach S, Giunti S, et al. Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: F1817-F1824
41. Watson AM, Gray SP, Jiaze L, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 2012; 61: 2105-2113
42. Weibel ER. Stereological methods. In Practical Methods for Biological Morphometry. Academic: London, UK, 1979 pp 51-57